Irinotecan (CPT-11) combined with UFT as first line treatment of advanced colorectal carcinoma-A phase II study.

被引：0
|
作者：
Cohen, Y
Shulman, K
Idelevich, E
Ben-Shachar, M
Honnigman, J
Haiat, H
Zidan, J
Hubert, A
Kuten, A
Beny, A
机构：
[1] Soroka Med Ctr, Beer Sheva, Israel
[2] Rambam Med Ctr, Haifa, Israel
[3] Kaplan Med Ctr, Rehovot, Israel
[4] Nahariya Med Ctr, Nahariyya, Israel
[5] HaEmek Med Ctr, Afula, Israel
[6] Wolfson Med Ctr, Holon, Israel
[7] Ziv Med Ctr, Sefad, Israel
[8] Hadassah Med Ctr, IL-91120 Jerusalem, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3742
引用
收藏
页码：304S / 304S
页数：1
相关论文
共 50 条
  • [31] Phase II trial and pharmacokinetic study of irinotecan (CPT-11) in patients with glioblastoma
    Boige, V
    Raymond, E
    Fabbro, M
    Plazza, J
    Vassal, G
    Risse, ML
    Rodier, JM
    Armand, JP
    ANNALS OF ONCOLOGY, 1998, 9 : 137 - 137
  • [32] Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC).
    Muñoz, A
    Salud, A
    Alonso, V
    Escudero, P
    Sanz, JJ
    Martín, C
    Rivera, F
    Yubero, A
    García-Girón, C
    López-Vivanco, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 272S - 272S
  • [33] First results of a novel study of irinotecan (CPT-11) in patients with advanced esophageal squamous cell carcinoma and adenocarcinoma
    Muehr-Wilkenshoff, FB
    Grabowski, P
    Hinkelbein, WG
    Ohnesorge, I
    Wolf, KJ
    Schulzke, JD
    Scheruebl, H
    GASTROENTEROLOGY, 2001, 120 (05) : A443 - A443
  • [34] Phase II study of irinotecan (CPT-11) in patients with advanced colorectal cancer resistant to 5-fluorouracil based chemotherapy.
    Salinas, P
    Lara, MA
    de Septién, CFM
    Feliu, J
    Espinosa, E
    de Castro, J
    García-Girón, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S76 - S76
  • [35] Lower than standard doses of irinotecan (cpt-11) in the treatment of metastatic colorectal carcinoma (MCC)
    Nikolic-Tomasevic, Z
    Jelic, S
    Tomasevic, ZM
    Radulovic, S
    Radosavljevic, D
    Popov, I
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 305S - 305S
  • [36] A combination of oxaliplatin and UFT-I-leucovorin as first line treatment in advanced colorectal cancer.: An ONCOPAZ phase II study.
    De Castro, J
    Vicent, J
    García-Girón, C
    Constela, M
    Fonseca, E
    Montalar, J
    Lomas, M
    Antón-Aparicio, L
    Dorta, F
    González-Barón, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 300S - 300S
  • [37] EFFICACY OF COMBINATION CHEMOTHERAPY WITH IRINOTECAN (CPT-11) PLUS CAPECITABINE IN PATIENTS WITH METASTATIC OR ADVANCED COLORECTAL CARCINOMA
    Gennatas, C.
    Michalaki, V.
    Gennatas, S.
    Voros, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 148 - 148
  • [38] Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer
    Alonso, V
    Escudero, P
    Zorrilla, M
    Isla, MD
    Herrero, A
    Mayordomo, JI
    Martinez-Trufero, J
    Sáenz, A
    Tres, A
    Antón, A
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (18) : 2385 - 2391
  • [39] Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial
    Holtan, S. G.
    Foster, N. R.
    Erlichman, C. E.
    Aubry, M.
    Ames, M. M.
    Safgren, S.
    Steen, P. D.
    Morton, R. F.
    Graham, D.
    Goetz, M. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma. Retrospective comparison
    Gluzman, A.
    Rubinov, K.
    Man, S.
    Lavrenkov, K.
    Ariad, S.
    ANNALS OF ONCOLOGY, 2006, 17 : 72 - 72
12345